CardioComm Solutions, Inc.
TSX VENTURE : EKG

CardioComm Solutions, Inc.

March 01, 2012 15:49 ET

CardioComm Solutions Issues Employee Stock Options and Completes a Round of Meetings at HIMMS

TORONTO, ONTARIO--(Marketwire - March 1, 2012) - CardioComm Solutions, Inc. (http://www.cardiocommsolutions.com) ("CardioComm Solutions" or the "Company") (TSX VENTURE:EKG) today announced that an aggregate of 1,023,750 incentive stock options have been granted to Company employees. The options are exercisable at $0.60 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.

"It has been a great few weeks and with the recent sales of shares and the exercising of options and warrants by insiders, staff and long term investors, it has been satisfying to see these stakeholders able to recover their initial financial and work ethic investments," reported Etienne Grima, CEO of the Company.

"Our option pool is in place to reward excellence and with this in mind, we are issuing a new round of options to our staff. We are very proud of our employees in the Toronto and Victoria offices and of their hard and dedicated work in getting the Company to achieve so much in such a short period of time. These employees form the core R&D, programming, customer support, sales and operations team and we are happy to have them participate in the continued growth of our company and to meet the demands that are on the way," said Anatoly Langer, Chairman of the Board.

To this point, late last month CardioComm Solutions' CEO attended the annual HealthCare Information Management Systems Society Meeting ("HIMMS"). HIMSS is an organization exclusively focused on providing global leadership for the optimal use of information technology and management systems for the betterment of healthcare. "HIMMS is a massive meeting with representation from all leaders in the medical information management sector. It was striking that despite the advances and investments made in tele and home medicine, there is still a void in the provisioning of ECG services in people's homes, disease management monitoring programs, outpatient ambulatory settings and in-ambulance ECG monitoring and triaging. Our GEMS™ platform and web based solutions were well received and new discussions are ensuing," stated Grima. A highlight for the Company was an invitation to attend a closed meeting sponsored by Qualcomm Life (www.qualcommlife.com) and Cooley LLP (www.cooley.com/index.aspx) and organized by Greenspring Associates (www.greenspringassociates.com) entitled The Consumer's Role in Disrupting Healthcare Delivery & Business Strategies Which Will Empower Them. The invitation-only meeting was attended by approximately 30 CEOs from leading companies active in medical technology delivery and innovations for the consumer medical markets. "HIMMS demonstrated that there are and will continue to be many opportunities opening to CardioComm Solutions, and the support of our staff and our shareholders will be very important as we push to meet response to the HeartCheck™ PEN OTC clearance as a consumer product and expansion of our medical (C4) and consumer (Smart Monitoring) services."

About CardioComm Solutions

CardioComm Solution's patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. CardioComm Solutions also is cleared by the FDA for the sales of a consumer based HeartCheck™ PEN (www.theheartcheck.com) handheld ECG device and home version of its proprietary GEMS™ Home software. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information